AUTOIMMUNE MYELOFIBROSIS ASSOCIATED WITH LUPUS: UNUSUAL OR UNDETECTED?

Received: June 13, 2021
Accepted: June 16, 2021

Durga Prasanna Misra* https://orcid.org/0000-0002-5035-7396
1Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

*Corresponding author: Durga Prasanna Misra, Associate Professor, DM, Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India.

Twitter handle: @DurgaPrasannaM1; E-mail: durgapmisra@gmail.com

Keywords: Autoimmune myelofibrosis, Diagnostics, Hypothesis, Systemic lupus erythematosus


Systemic lupus erythematosus (SLE) is a systemic autoimmune disease more commonly affecting young females. Hematological manifestations are one of the important clinical features of patients with SLE. Hemolytic anemia, leucopenia (predominantly lymphopenia), thrombocytopenia, and less commonly pancytopenia may be found in up to four-fifth of patients with SLE and form part of the classification criteria commonly used for lupus [1, 2]. Autoimmune myelofibrosis (AIMF) associated with lupus is one of the less common scenarios reported to cause cytopenias in SLE. In this issue of the Journal, Cansu et al. propose that AIMF might not be as rare as it has been described in the literature, and might actually be underrecognized [3]. AIMF is underrecognized in lupus. Patients with pancytopenia in the context of lupus would generally undergo bone marrow examination. In such instances, a hyperactive bone marrow would indicate peripheral destruction of erythrocytes, leucocytes, and thrombocytes. On the other hand, a hypocellular marrow would indicate marrow suppression, whether related to antibodies to stem cell precursors, gelatinous transformation of bone marrow, or myelofibrosis resulting in myelophthisic anemia [1, 4-6]. This is precisely the reason why the hypothesis that AIMF is underreported (rather than uncommon) might not be valid.

It is still possible that AIMF might be underreported in the literature owing to its rarity and the difficulty in publishing isolated case reports in the present publishing scenario. Therefore, the hypothesis proposed by Cansu et al still requires to be tested in real-life situations to assess its validity [3]. A first step towards testing this hypothesis could involve sending questionnaires to consultants leading lupus clinics across a geographic region or regions. Such questionnaires could assess what proportion of patients from these clinics have actually been suspected to have AIMF and how many actually underwent a bone marrow examination to look for
myelofibrosis. Should the frequency of myelofibrosis in lupus detected by such means far exceed that in the reported literature, then such findings should be prospectively verified in longitudinal cohorts of patients with lupus. As the authors have rightly proposed [3], stringent criteria delineating the need for bone marrow examination in patients with lupus might help detect rarer hematological manifestations such as AIMF more frequently. However, as pointed out previously, the overall prevalence of AIMF in lupus is still likely to be low due to the fact that severe pancytopenia per se is rare in lupus.

FUNDING
No funding was received for this commentary.

CONFLICTS OF INTEREST
Durga Prasanna Misra declares that he has no conflict of interest, including no relationship with pharmaceutical companies.

REFERENCES

АУТОИММУННЫЙ МИЕЛОФИБРОЗ, АССОЦИИРОВАННЫЙ С ВОЛЧАНКОЙ: РЕДКАЯ ИЛИ НЕ ВЫЯВЛЯЕМАЯ МАНИФЕСТАЦИЯ?

Ключевые слова: Аутоиммунный миелофибroz, Диагностика, Гипотезы, Системная красная волчанка